PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic alliance to enhance supply chain resilience, improve operational efficiency, and support the long-term growth of both organizations.
Through this alliance, PolyPeptide will broaden its sourcing options for key materials, establishing a more robust and flexible supply chain for peptide manufacturing. The agreement sets a framework for long-term cooperation, including integrated procurement and supply planning for select raw materials. Both companies are committed to maintaining high standards of quality, reliability, and compliance.
“Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including metabolics demand,” said Dr. Stéphane Varray, Chief Commercial Officer, PolyPeptide. “When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”
[…]